BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-141@catalystbrief.girapphe.com
DTSTAMP:20261118T181545Z
LAST-MODIFIED:20261118T181545Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: Innovent Biologics (Suzhou) Co. Ltd. — Aflibercept Ophth
 almic [Feb 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Evaluate the Efficacy an
 d Safety of IBI302 in Subjects With nAMD.\nSource: https://clinicaltrials.
 gov/study/NCT05972473\nhttps://catalystbrief.girapphe.com/e/141?lang=en\nN
 ot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/141?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
